GlaxoSmithKline Laval facility becomes North America vaccine research and development headquarters
$50 million investment to support new role
15-Jun-2007 -
GlaxoSmithKline (GSK) has designated its facility in Laval, Quebec, as the North American headquarters of its innovative vaccines division. The site will conduct leading vaccine research & development (R&D), and is also the administrative centre for the company's vaccines operations in North ...
allergies
GSK
immunology
+4